Work

ELECTRONIC SUPPLEMENTARY MATERIAL―Online Only from Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor

Year: 2023

Type: other

Abstract: Compiled Supplementary Data

DOI: 10.1158/1078-0432.22480382

Authors: David S. Hong, Kathleen N. Moore, Johanna C. Bendell, Daniel D. Karp, Judy S. Wang, Susanna V. Ulahannan, Suzanne Jones, Wenjuan Wu, Gregory P. Donoho, Yan Ding, Andrew Capen, Xuejing Wang, Aimee Bence Lin, Manish R. Patel

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Funder: National Institutes of Biomedical Innovation, Health and Nutrition

OpenAlex ID: W4361890481

Cites: 1

Cited by:

Related to: 10